Downstream Processing Featured Articles

71. Stratagene Introduces A New Product For Human Splice Variant Discovery 4/5/2006
    Stratagene Corporation, a developer, manufacturer and marketer of specialized life science research and diagnostic products, announced the commercial availability of the Human SpliceMiner cDNA Library Panel
72. Repligen Acquires Bioprocessing Business Of Refine Technology 6/3/2014

    Repligen Corporation announced recently that it has acquired the business of Refine Technology (“Refine”), including Refine’s Alternating Tangential Flow (“ATF”) System, a market-leading device used to significantly increase product yield during the fermentation step of the biologic drug manufacturing process.

73. Waters UltraPerformance Convergence Chromatography Ushers In New Category Of Separation Science At Pittcon 3/13/2012
    Waters Corporation recently drew back the curtain on several important new technologies and a new business venture at Pittcon 2012, the industry’s most important annual new product conference and exhibition.
74. Lonza And Sartorius Stedim Biotech Enter Collaboration, Supply And Distribution Agreement In The Field Of Cell Culture Media 12/19/2012

    Lonza recently announced together with Sartorius Stedim Biotech (SSB), a leading international pharmaceutical and biotech supplier, a long-term global collaboration, supply and distribution agreement in the field of cell culture media.

75. NIH Scientists Shed Light On Mystery Surrounding Hepatitis B Virus 1/8/2013

    Scientists from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health, and the University of Oxford, U.K., have shed light on a long-standing enigma about the structure of a protein related to the Hepatitis B virus.

76. Merck Assesses Single Use: Does It Make Sense At A Large Scale? 5/14/2014

    In an industry as conservative as the pharmaceutical industry, it is common practice to be adverse to new technologies because they are often viewed as too much of a risk. However, in this effort to play it safe, companies force themselves into a repetitive state of employing technologies that may not be the most efficient or effective. Rather than getting stuck in old habits — or conversely, jumping too quickly into new ones — Merck has put together a group of teams it calls the Technology Encouragement Collaborators, or TEC, to look at new technologies and determine whether or not to implement them.

77. Sanford-Burnham Research Projects Selected To Go To Space 11/29/2012

    We’re excited to announce recently that two of our research teams have won Space Florida’sInternational Space Station (ISS) Research Competition. Eight teams were selected from a pool of international applicants to send experiments to space in late 2013.

78. Dr. Reddy's Laboratories Ltd. And Merck Serono Announce Collaboration To Develop And Commercialize Biosimilars 6/6/2012

    Dr. Reddy’s Laboratories Ltd. [NYSE:RDY] and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). The partnership covers co-development, manufacturing and commercialization of the compounds around the globe, with some specific country exceptions.

79. Lonza And OncoMed Pharmaceuticals Sign A Process Development And Manufacturing Collaboration And Multi-Product GS License Agreement For Anti-Cancer Therapeutics 10/23/2012

    Lonza, a global leader in biological manufacturing and OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to improving cancer treatment, announced recently an agreement for the development and manufacture of OncoMed’s pipeline of anti-cancer stem cell therapeutics.

80. NIH-Funded Researchers Create Next-Generation Alzheimer's Disease Model 4/9/2013

    A new genetically engineered lab rat that has the full array of brain changes associated with Alzheimer’s disease supports the idea that increases in a molecule called beta-amyloid in the brain causes the disease, according to a study, published in the Journal of Neuroscience.